Laboratory Testing for Bone and Joint Pain
For patients presenting with bone and joint pain, order a core panel of inflammatory markers (ESR and CRP), complete blood count with differential, and renal function tests at baseline, with additional targeted testing based on clinical presentation—specifically rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA) when inflammatory arthritis is suspected, and metabolic bone markers (alkaline phosphatase, calcium, vitamin D, phosphate, parathyroid hormone) when metabolic bone disease is considered.
Core Laboratory Panel (Order Routinely)
The following tests should be performed in all patients with bone and joint pain 1:
- Complete blood count with white blood cell differential - assesses systemic inflammation and rules out hematologic abnormalities
- Inflammatory markers: ESR and CRP - both should be ordered at baseline 2. While CRP alone may be less predictive, the combination provides diagnostic value for inflammatory conditions
- Renal function - essential for medication safety assessment 1
- Metabolic bone panel:
- Alkaline phosphatase
- Calcium
- 25-hydroxy-vitamin D
- Phosphate
- Parathyroid hormone
This metabolic panel excludes osteomalacia, Paget's disease, and hypophosphatasia 1.
Targeted Testing Based on Clinical Presentation
When Inflammatory Arthritis is Suspected
Order RF and ACPA testing - these are strongly predictive of rheumatoid arthritis diagnosis and prognosis 2. The evidence for ACPA and RF is compelling for RA diagnosis at follow-up. However, negative tests do not exclude progression to RA 2.
When Axial Involvement or Inflammatory Back Pain is Present
Consider HLA-B27 typing - supports diagnosis of axial spondyloarthritis when positive 1, 2.
When Systemic Inflammatory Disorder is Suspected
Consider additional autoantibody testing on a case-by-case basis 2:
- Antinuclear antibodies (ANA)
- Antibodies to extractable nuclear antigens
- Anti-double-stranded DNA antibodies
Optional Advanced Testing
Bone turnover markers (P1NP and CTx) - can be determined in fasting blood samples to aid evaluation of metabolic bone diseases 1. These are not routine but useful when metabolic bone disease remains in the differential.
Critical Pitfalls to Avoid
Do not order an indiscriminate "arthritis panel" 3. Laboratory testing must be guided by clinical context from history and physical examination.
Inflammatory markers have limitations - ESR and CRP are susceptible to aseptic inflammatory confounders and should not be used as standalone diagnostic tests 4. They are screening tools, not confirmatory tests.
Negative autoantibodies do not exclude disease - particularly for RF and ACPA in early inflammatory arthritis 2.
When Joint Fluid Analysis is Superior
If joint effusion is present, arthrocentesis provides the best diagnostic yield compared to serum testing 3, 5. Synovial fluid analysis should include:
- White blood cell count and differential (sensitivity 0.84, specificity 0.84) 5
- Percentage of polymorphonuclear cells (sensitivity 0.75, specificity 0.92) 5
- Crystal analysis
- Gram stain and culture
Novel synovial fluid biomarkers (calprotectin and alpha-defensin) offer exceptional diagnostic specificity for infection when available 4.
Algorithm for Laboratory Testing
- All patients: Core panel (CBC, ESR/CRP, renal function, metabolic bone markers)
- Polyarticular involvement or small joint symmetry: Add RF and ACPA
- Axial symptoms or inflammatory back pain: Add HLA-B27
- Systemic features or extra-articular manifestations: Add targeted autoantibodies
- Joint effusion present: Prioritize arthrocentesis over additional serum testing
- Suspected infection: Synovial fluid analysis with culture; consider novel biomarkers if available
The diagnostic framework has shifted from seeking a single diagnostic marker toward multimodal assessment 4. Laboratory results must always be interpreted within the clinical context established by detailed history and physical examination 6, 3.